Company Active LTD

Company profile

Immunobiology Limited

403 Forbidden

Immunobiology Limited is a UK company with status active founded in 1999 based in East of England.

CRN
03777578
Founded
1999
Age
27

Overview

Legal name
IMMUNOBIOLOGY LIMITED
Region
East of England
Registered address
BABRAHAM RESEARCH CAMPUS
BABRAHAM
CAMBRIDGE
CB22 3AT
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Immunobiology Limited
CRN 03777578
2
Direct and ultimate controller Active PLC

Latest accounts

Financial period: 1 Jun 2023 to 31 May 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
3

Company events

Reference milestones and recent Companies House filing stream events.

5 events
13 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

28 Feb
2026

Accounts due

Accounts Due

Next accounts due date

27 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 May
2024

Accounts filed

Accounts

Last accounts made up date

26 May
1999

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2007
Funded years
2007, 2009, 2012, 2013
Age at first award
8 years

Projects

2013 Feasibility Studies Lead participant

Low cost, broadly efficacious Pneumococcal vaccine

1 Apr 2013 to 31 Mar 2014

Awarded
£146,993
Total cost £198,130

Immunisation programmes have proven successful against some of the world’s most deadly diseases but unfortunately vaccines are not available to protect against many existing infections and new vaccine approaches are required urgently to prevent evolving and emerging diseases. For example, vaccines are not available to protect against some strains of bacte...

2013 GRD Proof of Market Lead participant

Market viability of ImmBioVax vaccines against H. Pylori and C. Difficile

1 Mar 2013 to 30 Sep 2013

Awarded
£24,500
Total cost £41,500

Vaccines are not yet available to protect against H. Pylori and C. Difficile and the existing therapeutic options available have significant limitations and challenges. Although quoted as significant, the market size for vaccines against these pathogens are poorly defined and the characteristics of a successful prophylactic vaccine product (e.g. productio...

2012 Collaborative R&D Lead participant

Development of a Universal Meningococcal Vaccine

1 Dec 2012 to 31 May 2014

Awarded
£490,000
Total cost £980,196

Vaccine immunisation programmes have proven successful against some of the world’s most deadly diseases, eradicating smallpox and on the edge of eradicating Polio. Unfortunately, vaccines are not available to protect against many existing infections and new vaccine approaches are required to stop evolving and emerging diseases. For example, while vaccines...

2009 Collaborative R&D Lead participant

Manufacture of Low Cost High Efficacy Vaccine

1 Oct 2009 to 30 Sep 2011

Awarded
£178,881
Total cost £405,717

Awaiting Public Summary

2007 Collaborative R&D Lead participant

Biomanufacture of HspC Vaccines Against Bacterial Pathogens

1 Sep 2007 to 31 Aug 2009

Awarded
£12,929
Total cost £334,056

Awaiting Public Summary

Product types

Collaborative R&D Feasibility Studies GRD Proof of Market